ReviewNature reviews. Urology2010
Repeat botulinum toxin-A injections for treatment of adult detrusor overactivity.
Review in Nature reviews. Urology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Review
- Effect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium.Neurourology and urodynamics · 2015Article
- Review
- Repeated botulinum toxin type A (Dysport) injections for women with intractable detrusor overactivity: a prospective outcome study.International urogynecology journal · 2014Article
- Onabotulinum toxin a (botox®) in the treatment of neurogenic bladder overactivity.Nephro-urology monthly · 2012Article
- Neurogenic detrusor overactivity in patients with spinal cord injury: evaluation and management.Current urology reports · 2011Review
- Moving beyond ineffective medication for OAB.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2011Article
- Botulinum toxin A should not be first-line therapy for overactive bladder.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2011Article
- Botulinum toxin A: First-line therapy for idiopathic detrusor overactivity.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2011Article
- Highlights of the university of toronto urology update 2014.Canadian Urological Association journal = Journal de l'Association des urologues du CanadaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Intravesical injections of botulinum toxin-A have become established as an effective therapy in the management of neurogenic and idiopathic detrusor overactivity that is refractory to treatment with anticholinergic medication. The effects of the toxin are finite and repeated injections are required to sustain the beneficial therapeutic effects. The available data suggest a reproducible and sustained improvement in symptoms as well as urodynamic parameters following repeated injections of botulinum toxin-A. The reported incidence of adverse events is low and resistance to the toxin is uncommon. The timing of repeat injections within the published data is variable, reflecting differing practise among clinicians, but is typically 6-12 months. Larger scale studies are still required to clarify the usefulness of botulinum toxin-A as a long-term treatment in the management of detrusor overactivity.
Indexed as
Identifiers
21139642What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.